Nivolumab for treating advanced (unresectable or metastatic) melanoma

  • Technology appraisal guidance
  • TA384
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1

Nivolumab as monotherapy is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults.